Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 6/2013

01-12-2013 | Diabetes Epidemiology (SH Golden, Section Editor)

Environmental Chemicals and Type 2 Diabetes: An Updated Systematic Review of the Epidemiologic Evidence

Authors: Chin-Chi Kuo, Katherine Moon, Kristina A. Thayer, Ana Navas-Acien

Published in: Current Diabetes Reports | Issue 6/2013

Login to get access

Abstract

The burden of diabetes is increasing globally. Identifying novel preventable risk factors is an urgent need. In 2011, the U.S. National Toxicological Program (NTP) conducted a workshop to evaluate the epidemiologic and experimental evidence on the relationship of environmental chemicals with obesity, diabetes, and metabolic syndrome. Although the evidence was insufficient to establish causality, the NTP workshop review identified an overall positive association between some environmental chemicals and diabetes. In the present systematic review, our objective was to summarize the epidemiological research published since the NTP workshop. We identified a total of 29 articles (7 on arsenic, 3 on cadmium, 2 on mercury, 11 on persistent organic pollutants, 3 on phthalates, and 4 on bisphenol A), including 7 prospective studies. Considering consistency, temporality, strength, dose–response relationship, and biological plausibility (confounding), we concluded that the evidence is suggestive but not sufficient for a relationship between arsenic and persistent organic pollutants and is insufficient for mercury, phthalates, and bisphenol A. For cadmium, the epidemiologic evidence does not seem to suggest an association with diabetes. Important research questions include the need for additional prospective studies and the evaluation of the dose–response relationship, the role of joint exposures, and effect modification with other comorbidities and genetic variants.
Literature
1.
World Health Organization (WHO). Diabetes. In: 2013.
2.
Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.PubMedCrossRef
3.
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.PubMedCrossRef
4.
Centers for Disease Control and Prevention (CDC). National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. In: U.S. Department of Health and Human Services.CDC (Editor) Atlanta, GA; 2011.
5.
Buse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors. Williams textbook of endocrinology. Philadelphia: Elsevier Saunders; 2011. p. 1371–435.CrossRef
6.
Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011;17:287–302.PubMedCrossRef
7.
Conditions TNCCfC. TYPE 2 DIABETES, National clinical guideline for management in primary and secondary care (update). In: London: Royal College of Physicians; 2008.
8.
American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013;36 Suppl 1:S11–66.CrossRef
9.
Grandjean P. Exposure to environmental chemicals as a risk factor for diabetes development. In: Bourguignon J-P, Jégou B, Kerdelhué B, et al., editors. Multi-system endocrine disruption. Berlin: Springer; 2011. p. 91–9.CrossRef
10.
• Thayer KA, Heindel JJ, Bucher JR, Gallo MA. Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. Environ Health Perspect. 2012;120:779–89. This review article provides a thorough and transparent review of the role of environmental chemicals in diabetes and is the starting point for this review.PubMedCrossRef
11.
National Toxicology Program (NTP). NTP Workshop: role of environmental chemicals in the development of diabetes and obesity. In: 2011.
12.
• Maull EA, Ahsan H, Edwards J, et al. Evaluation of the Association between arsenic and diabetes: a National Toxicology Program Workshop Review. Environ Health Perspect. 2012;120:1658–70. This article provides a thorough review of the role of arsenic in diabetes development from epidemiological and experimental perspectives. It also covered several open research challenges that warrant future research.PubMed
13.
• Taylor KW, Novak RF, Anderson HA, et al. Evaluation of the Association between Persistent Organic Pollutants (POPs) and Diabetes in Epidemiological Studies: a National Toxicology Program Workshop Review. Environ Health Perspect. 2013. This article provides a comprehensive review of the role of persistent organic pollutants in diabetes development and serves as a reference point for this review.
14.
Behl M, Rao D, Aagaard K, et al. Evaluation of the association between maternal smoking, childhood obesity, and metabolic disorders: a national toxicology program workshop review. Environ Health Perspect. 2013;121:170–80.PubMed
15.
Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2007;298:2654–64.PubMedCrossRef
16.
Pearson JF, Bachireddy C, Shyamprasad S, et al. Association between fine particulate matter and diabetes prevalence in the U.S. Diabetes Care. 2010;33:2196–201.PubMedCrossRef
17.
Rajagopalan S, Brook RD. Air pollution and type 2 diabetes: mechanistic insights. Diabetes. 2012;61:3037–45.PubMedCrossRef
18.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. W64.PubMedCrossRef
19.
The 2004 United States Surgeon General's Report: the Health Consequences of Smoking. N S W Pub Health Bull. 2004;15:107.
20.
National Toxicology Program. Draft OHAT approach for systematic review and evidence integration for literature-based health assessments - February 2013. In: U.S. Department of Health and Human Services (Editor). 2013.
21.
Navas-Acien A, Nachman KE. Public health responses to arsenic in rice and other foods. JAMA Intern Med. 2013:1–2.
22.
World Health Organization (WHO). Arsenic. 2012.
23.
World Health Organization (WHO). Environmental health criteria document 224. arsenic and arsenic compounds. In: The International Programme on Chemical Safety. (IPCS) (Editor). 2001.
24.
International Agency for Research on Cancer (IARC). Summaries and evaluations. Arsenic in drinking water (group 1). Vol.84. In: Lyon: 2004.
25.
Tseng CH, Tai TY, Chong CK, et al. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect. 2000;108:847–51.PubMedCrossRef
26.
Rahman M, Tondel M, Ahmad SA, Axelson O. Diabetes mellitus associated with arsenic exposure in Bangladesh. Am J Epidemiol. 1998;148:198–203.PubMedCrossRef
27.
Coronado-Gonzalez JA, Del Razo LM, Garcia-Vargas G, et al. Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ Res. 2007;104:383–9.PubMedCrossRef
28.
Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. Rejoinder: arsenic exposure and prevalence of type 2 diabetes: updated findings from the National Health Nutrition and Examination Survey, 2003–2006. Epidemiology. 2009;20:816–20. discussion e1-2.PubMedCrossRef
29.
Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA. 2008;300:814–22.PubMedCrossRef
30.
Navas-Acien A, Silbergeld EK, Streeter RA, et al. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect. 2006;114:641–8.PubMedCrossRef
31.
Davey JC, Nomikos AP, Wungjiranirun M, et al. Arsenic as an endocrine disruptor: arsenic disrupts retinoic acid receptor-and thyroid hormone receptor-mediated gene regulation and thyroid hormone-mediated amphibian tail metamorphosis. Environ Health Perspect. 2008;116:165–72.PubMedCrossRef
32.
Davey JC, Bodwell JE, Gosse JA, Hamilton JW. Arsenic as an endocrine disruptor: effects of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol Sci. 2007;98:75–86.PubMedCrossRef
33.
Douillet C, Currier J, Saunders J, et al. Methylated trivalent arsenicals are potent inhibitors of glucose stimulated insulin secretion by murine pancreatic islets. Toxicol Appl Pharmacol. 2013;267:11–5.PubMedCrossRef
34.
Tseng CH. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol Appl Pharmacol. 2004;197:67–83.PubMedCrossRef
35.
Diaz-Villasenor A, Burns AL, Hiriart M, et al. Arsenic-induced alteration in the expression of genes related to type 2 diabetes mellitus. Toxicol Appl Pharmacol. 2007;225:123–33.PubMedCrossRef
36.
Druwe IL, Vaillancourt RR. Influence of arsenate and arsenite on signal transduction pathways: an update. Arch Toxicol. 2010;84:585–96.PubMedCrossRef
37.
Bodwell JE, Gosse JA, Nomikos AP, Hamilton JW. Arsenic disruption of steroid receptor gene activation: complex dose–response effects are shared by several steroid receptors. Chem Res Toxicol. 2006;19:1619–29.PubMedCrossRef
38.
Fry RC, Navasumrit P, Valiathan C, et al. Activation of inflammation/NF-kappaB signaling in infants born to arsenic-exposed mothers. PLoS Genet. 2007;3:e207.PubMedCrossRef
39.
Smeester L, Rager JE, Bailey KA, et al. Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011;24:165–7.PubMedCrossRef
40.
Kim Y, Lee BK. Association between urinary arsenic and diabetes mellitus in the Korean general population according to KNHANES 2008. Sci Total Environ. 2011;409:4054–62.PubMedCrossRef
41.
Islam R, Khan I, Hassan SN, et al. Association between type 2 diabetes and chronic arsenic exposure in drinking water: a cross sectional study in Bangladesh. Environ Health. 2012;11:38.PubMedCrossRef
42.
Makris KC, Christophi CA, Paisi M, Ettinger AS. A preliminary assessment of low level arsenic exposure and diabetes mellitus in Cyprus. BMC Public Health. 2012;12:334.PubMedCrossRef
43.
Gribble MO, Howard BV, Umans JG, et al. Arsenic exposure, diabetes prevalence, and diabetes control in the Strong Heart Study. Am J Epidemiol. 2012;176:865–74.PubMedCrossRef
44.
James KA, Marshall JA, Hokanson JE, et al. A case-cohort study examining lifetime exposure to inorganic arsenic in drinking water and diabetes mellitus. Environ Res. 2013;123:33–8.PubMedCrossRef
45.
Kim NH, Mason CC, Nelson RG, et al. Arsenic exposure and incidence of type 2 diabetes in Southwestern American Indians. Am J Epidemiol. 2013.
46.
Li X, Li B, Xi S, et al. Prolonged environmental exposure of arsenic through drinking water on the risk of hypertension and type 2 diabetes. Environ Sci Pollut Res Int. 2013.
47.
Swaddiwudhipong W, Mahasakpan P, Limpatanachote P, Krintratun S. Correlations of urinary cadmium with hypertension and diabetes in persons living in cadmium-contaminated villages in northwestern Thailand: a population study. Environ Res. 2010;110:612–6.PubMedCrossRef
48.
Barregard L, Bergstrom G, Fagerberg B. Cadmium exposure in relation to insulin production, insulin sensitivity and type 2 diabetes: a cross-sectional and prospective study in women. Environ Res. 2013;121:104–9.PubMedCrossRef
49.
Moon SS. Association of lead, mercury and cadmium with diabetes in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009–2010. Diabet Med. 2013;30:e143–8.PubMedCrossRef
50.
• He K, Xun P, Liu K, et al. Mercury exposure in young adulthood and incidence of diabetes later in life: the CARDIA Trace Element Study. Diabetes Care. 2013;36:1584–9. This large prospective study with a long-term follow-up period was conducted in young adults. Furthermore, the authors also evaluated insulin resistance and pancreatic cell function longitudinally to explore potential pathophysiological mechanisms linking mercury exposure to diabetes development.PubMedCrossRef
51.
Del Razo LM, Garcia-Vagras GG, Valenzuela OL, et al. Exposure to arsenic in drinking water is associated with increased prevalence of diabetes: a cross-sectional study in the Zimapan and Lagunera Regions in Mexico. Environ Heal. 2011;10:73.CrossRef
52.
World Health Organization (WHO). Exposure to cadmium: a major public health concern. In: Switzerland: 2010.
53.
World Health Organization (WHO). Mercury and health. In: 2012.
54.
Chen YW, Yang CY, Huang CF, et al. Heavy metals, islet function and diabetes development. Islets. 2009;1:169–76.PubMedCrossRef
55.
Chen YW, Huang CF, Yang CY, et al. Inorganic mercury causes pancreatic beta-cell death via the oxidative stress-induced apoptotic and necrotic pathways. Toxicol Appl Pharmacol. 2010;243:323–31.PubMedCrossRef
56.
Edwards JR, Prozialeck WC. Cadmium, diabetes and chronic kidney disease. Toxicol Appl Pharmacol. 2009;238:289–93.PubMedCrossRef
57.
Schwartz GG, Il'yasova D, Ivanova A. Urinary cadmium, impaired fasting glucose, and diabetes in the NHANES III. Diabetes Care. 2003;26:468–70.PubMedCrossRef
58.
Selin NE, Sunderland EM, Knightes CD, Mason RP. Sources of mercury exposure for U.S. seafood consumers: implications for policy. Environ Health Perspect. 2010;118:137–43.PubMed
59.
Xun P, He K. Fish consumption and incidence of diabetes: meta-analysis of data from 438,000 individuals in 12 independent prospective cohorts with an average 11-year follow-up. Diabetes Care. 2012;35:930–8.PubMedCrossRef
60.
Lind L, Lind PM. Can persistent organic pollutants and plastic-associated chemicals cause cardiovascular disease? J Intern Med. 2012;271:537–53.PubMedCrossRef
61.
Porta M, Puigdomenech E, Ballester F, et al. Monitoring concentrations of persistent organic pollutants in the general population: the international experience. Environ Int. 2008;34:546–61.PubMedCrossRef
62.
Gasull M, Pumarega J, Tellez-Plaza M, et al. Blood concentrations of persistent organic pollutants and prediabetes and diabetes in the general population of Catalonia. Environ Sci Technol. 2012;46:7799–810.PubMedCrossRef
63.
European Commission. Persistent Organic Pollutants. 2012.
64.
World Health Organization (WHO). Persistent organic pollutants (POPs). In: Children's health and the environment; WHO Training Package for the Health Sector.; 2008.
65.
Henriksen GL, Ketchum NS, Michalek JE, Swaby JA. Serum dioxin and diabetes mellitus in veterans of Operation Ranch Hand. Epidemiology. 1997;8:252–8.PubMedCrossRef
66.
Tanaka T, Morita A, Kato M, et al. Congener-specific polychlorinated biphenyls and the prevalence of diabetes in the Saku Control Obesity Program (SCOP). Endocr J. 2011;58:589–96.PubMedCrossRef
67.
Persky V, Piorkowski J, Turyk M, et al. Associations of polychlorinated biphenyl exposure and endogenous hormones with diabetes in post-menopausal women previously employed at a capacitor manufacturing plant. Environ Res. 2011;111:817–24.PubMedCrossRef
68.
Lee DH, Lind PM, Jacobs Jr DR, et al. Polychlorinated biphenyls and organochlorine pesticides in plasma predict development of type 2 diabetes in the elderly: the prospective investigation of the vasculature in Uppsala Seniors (PIVUS) study. Diabetes Care. 2011;34:1778–84.PubMedCrossRef
69.
Airaksinen R, Rantakokko P, Eriksson JG, et al. Association between type 2 diabetes and exposure to persistent organic pollutants. Diabetes Care. 2011;34:1972–9.PubMedCrossRef
70.
Silverstone AE, Rosenbaum PF, Weinstock RS, et al. Polychlorinated biphenyl (PCB) exposure and diabetes: results from the Anniston Community Health Survey. Environ Health Perspect. 2012;120:727–32.PubMedCrossRef
71.
Everett CJ, Thompson OM. Associations of dioxins, furans and dioxin-like PCBs with diabetes and pre-diabetes: is the toxic equivalency approach useful? Environ Res. 2012;118:107–11.PubMedCrossRef
72.
Persky V, Piorkowski J, Turyk M, et al. Polychlorinated biphenyl exposure, diabetes and endogenous hormones: a cross-sectional study in men previously employed at a capacitor manufacturing plant. Environ Health. 2012;11:57.PubMedCrossRef
73.
Nakamoto M, Arisawa K, Uemura H, et al. Association between blood levels of PCDDs/PCDFs/dioxin-like PCBs and history of allergic and other diseases in the Japanese population. Int Arch Occup Environ Health. 2012.
74.
Arrebola JP, Pumarega J, Gasull M, et al. Adipose tissue concentrations of persistent organic pollutants and prevalence of type 2 diabetes in adults from Southern Spain. Environ Res. 2013;122:31–7.PubMedCrossRef
75.
• Wu H, Bertrand KA, Choi AL, et al. Persistent organic pollutants and type 2 diabetes: a prospective analysis in the nurses' health study and meta-analysis. Environ Health Perspect. 2013;121:153–61. This study combined two nested case–control studies to evaluate the association between persistent organic pollutants (POPs) exposure and incident diabetes with an 18-year follow-up. The authors also conducted a meta-analysis to summarize recent prospective evidence regarding POPs and incident diabetes.PubMed
76.
Kerger BD, Scott PK, Pavuk M, et al. Re-analysis of Ranch Hand study supports reverse causation hypothesis between dioxin and diabetes. Crit Rev Toxicol. 2012;42:669–87.PubMedCrossRef
77.
78.
Lee DH, Steffes MW, Sjodin A, et al. Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes. PLoS One. 2011;6:e15977.PubMedCrossRef
79.
Turyk M, Anderson H, Knobeloch L, et al. Organochlorine exposure and incidence of diabetes in a cohort of Great Lakes sport fish consumers. Environ Health Perspect. 2009;117:1076–82.PubMed
80.
Rignell-Hydbom A, Lidfeldt J, Kiviranta H, et al. Exposure to p, p'-DDE: a risk factor for type 2 diabetes. PLoS One. 2009;4:e7503.PubMedCrossRef
81.
Wang SL, Tsai PC, Yang CY, Leon GY. Increased risk of diabetes and polychlorinated biphenyls and dioxins: a 24-year follow-up study of the Yucheng cohort. Diabetes Care. 2008;31:1574–9.PubMedCrossRef
82.
Vasiliu O, Cameron L, Gardiner J, et al. Polybrominated biphenyls, polychlorinated biphenyls, body weight, and incidence of adult-onset diabetes mellitus. Epidemiol. 2006;17:352–9.CrossRef
83.
84.
Kang HK, Dalager NA, Needham LL, et al. Health status of Army Chemical Corps Vietnam veterans who sprayed defoliant in Vietnam. Am J Ind Med. 2006;49:875–84.PubMedCrossRef
85.
Michalek JE, Pavuk M. Diabetes and cancer in veterans of Operation Ranch Hand after adjustment for calendar period, days of spraying, and time spent in Southeast Asia. J Occup Environ Med. 2008;50:330–40.PubMedCrossRef
86.
Steenland K, Calvert G, Ketchum N, Michalek J. Dioxin and diabetes mellitus: an analysis of the combined NIOSH and Ranch Hand data. Occup Environ Med. 2001;58:641–8.PubMedCrossRef
87.
James-Todd T, Stahlhut R, Meeker JD, et al. Urinary phthalate metabolite concentrations and diabetes among women in the National Health and Nutrition Examination Survey (NHANES) 2001–2008. Environ Health Perspect. 2012;120:1307–13.PubMedCrossRef
88.
Hauser R, Meeker JD, Park S, et al. Temporal variability of urinary phthalate metabolite levels in men of reproductive age. Environ Health Perspect. 2004;112:1734–40.PubMedCrossRef
89.
Stahlhut RW, van Wijngaarden E, Dye TD, et al. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environ Health Perspect. 2007;115:876–82.PubMedCrossRef
90.
Casals-Casas C, Feige JN, Desvergne B. Interference of pollutants with PPARs: endocrine disruption meets metabolism. Int J Obes (Lond). 2008;32 Suppl 6:S53–61.CrossRef
91.
Hurst CH, Waxman DJ. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci. 2003;74:297–308.PubMedCrossRef
92.
Hectors TL, Vanparys C, Pereira-Fernandes A, et al. Evaluation of the INS-1 832/13 cell line as a beta-cell based screening system to assess pollutant effects on beta-cell function. PLoS One. 2013;8:e60030.PubMedCrossRef
93.
Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 2009;30:293–342.PubMedCrossRef
94.
Feige JN, Gelman L, Rossi D, et al. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem. 2007;282:19152–66.PubMedCrossRef
95.
Latini G, Scoditti E, Verrotti A, et al. Peroxisome proliferator-activated receptors as mediators of phthalate-induced effects in the male and female reproductive tract: epidemiological and experimental evidence. PPAR Res. 2008;2008:359267.PubMedCrossRef
96.
Lind PM, Zethelius B, Lind L. Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderly. Diabetes Care. 2012;35:1519–24.PubMedCrossRef
97.
Svensson K, Hernandez-Ramirez RU, Burguete-Garcia A, et al. Phthalate exposure associated with self-reported diabetes among Mexican women. Environ Res. 2011;111:792–6.PubMedCrossRef
98.
Silva MJ, Barr DB, Reidy JA, et al. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999–2000. Environ Health Perspect. 2004;112:331–8.PubMedCrossRef
99.
Parlett LE, Calafat AM, Swan SH. Women's exposure to phthalates in relation to use of personal care products. J Expo Sci Environ Epidemiol. 2013;23:197–206.PubMedCrossRef
100.
Hoppin JA, Brock JW, Davis BJ, Baird DD. Reproducibility of urinary phthalate metabolites in first morning urine samples. Environ Health Perspect. 2002;110:515–8.PubMedCrossRef
101.
Global Agricultural Information Network (GAIN). French National Assembly supports BPA Ban Bill hastens implementation. In: USDA Foreign Agricultural Service; 2012.
102.
Joint food and agriculture organization of the united nations and world health organization (FAO/WHO). Joint food and agriculture organization of the united nations and world health organization (FAO/WHO) expert meeting to review toxicological and health aspects of bisphenol a: Final report, including report of stakeholder meeting on bisphenol A, 1–5 November 2010. In: Ottawa, Canada. 2011.
103.
Vandenberg LN, Maffini MV, Sonnenschein C, et al. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr Rev. 2009;30:75–95.PubMedCrossRef
104.
Vandenberg LN, Chahoud I, Heindel JJ, et al. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. Environ Health Perspect. 2010;118:1055–70.PubMedCrossRef
105.
Calafat AM, Ye X, Wong LY, et al. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003–2004. Environ Health Perspect. 2008;116:39–44.PubMedCrossRef
106.
Lakind JS, Naiman DQ. Daily intake of bisphenol A and potential sources of exposure: 2005–2006 National Health and Nutrition Examination Survey. J Expo Sci Environ Epidemiol. 2011;21:272–9.PubMedCrossRef
107.
Calafat AM, Weuve J, Ye X, et al. Exposure to bisphenol A and other phenols in neonatal intensive care unit premature infants. Environ Health Perspect. 2009;117:639–44.PubMed
108.
Biedermann S, Tschudin P, Grob K. Transfer of bisphenol A from thermal printer paper to the skin. Anal Bioanal Chem. 2010;398:571–6.PubMedCrossRef
109.
Hugo ER, Brandebourg TD, Woo JG, et al. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environ Health Perspect. 2008;116:1642–7.PubMedCrossRef
110.
Alonso-Magdalena P, Morimoto S, Ripoll C, et al. The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. Environ Health Perspect. 2006;114:106–12.PubMedCrossRef
111.
Ning G, Bi Y, Wang T, et al. Relationship of urinary bisphenol A concentration to risk for prevalent type 2 diabetes in Chinese adults: a cross-sectional analysis. Ann Intern Med. 2011;155:368–74.PubMedCrossRef
112.
Shankar A, Teppala S. Relationship between urinary bisphenol A levels and diabetes mellitus. J Clin Endocrinol Metab. 2011;96:3822–6.PubMedCrossRef
113.
Silver MK, O'Neill MS, Sowers MR, Park SK. Urinary bisphenol A and type-2 diabetes in U.S. adults: data from NHANES 2003–2008. PLoS One. 2011;6:e26868.PubMedCrossRef
114.
Kim K, Park H. Association between urinary concentrations of bisphenol A and type 2 diabetes in Korean adults: a population-based cross-sectional study. Int J Hyg Environ Health. 2013;216:467–71.PubMedCrossRef
115.
Lang IA, Galloway TS, Scarlett A, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA. 2008;300:1303–10.PubMedCrossRef
116.
Wang T, Li M, Chen B, et al. Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97:E223–7.PubMedCrossRef
117.
Magliano DJ, Lyons JG. Bisphenol A and diabetes, insulin resistance, cardiovascular disease and obesity: controversy in a (plastic) cup? J Clin Endocrinol Metab. 2013;98:502–4.PubMedCrossRef
118.
Braun JM, Kalkbrenner AE, Calafat AM, et al. Variability and predictors of urinary bisphenol A concentrations during pregnancy. Environ Health Perspect. 2011;119:131–7.PubMedCrossRef
119.
Braun JM, Smith KW, Williams PL, et al. Variability of urinary phthalate metabolite and Bisphenol A concentrations before and during pregnancy. Environ Health Perspect. 2012.
120.
Mahalingaiah S, Meeker JD, Pearson KR, et al. Temporal variability and predictors of urinary bisphenol A concentrations in men and women. Environ Health Perspect. 2008;116:173–8.PubMedCrossRef
121.
Ye X, Zhou X, Hennings R, et al. Potential external contamination with bisphenol A and other ubiquitous organic environmental chemicals during biomonitoring analysis: an elusive laboratory challenge. Environ Health Perspect. 2013;121:283–6.PubMedCrossRef
Metadata
Title
Environmental Chemicals and Type 2 Diabetes: An Updated Systematic Review of the Epidemiologic Evidence
Authors
Chin-Chi Kuo
Katherine Moon
Kristina A. Thayer
Ana Navas-Acien
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 6/2013
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-013-0432-6

Other articles of this Issue 6/2013

Current Diabetes Reports 6/2013 Go to the issue

Diabetes Epidemiology (SH Golden, Section Editor)

Race/Ethnic Difference in Diabetes and Diabetic Complications

Diabetes Epidemiology (SH Golden, Section Editor)

The Emerging Global Epidemic of Type 1 Diabetes

Psychosocial Aspects (KK Hood, Section Editor)

Positive Psychological Characteristics in Diabetes: A Review

Diabetes Epidemiology (SH Golden, Section Editor)

Social Epidemiology of Diabetes and Associated Conditions

Psychosocial Aspects (KK Hood, Section Editor)

Transition Readiness in Adolescents and Emerging Adults with Diabetes: The Role of Patient-Provider Communication

Psychosocial Aspects (KK Hood, Section Editor)

Utilization of Blood Glucose Data in Patient Education
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits